Loading
Profusa, Inc. Stock: price and insider trades · United States
1 insider bought €32k of shares over the last 90 days, the latest by HRT FINANCIAL LP, filed 14 Aug 2026.
Profusa, Inc.: what insiders have been doing
This page follows insider dealings at Profusa, Inc. as filed with SEC (Form 4), a company from the Health Care sector. 6 insiders have disclosed 25 filings since 22 October 2025.
The record shows 8 purchases on the open market worth €32k, made by 1 insider, against 6 sales worth €132k by 1 insider. Taken together, the sales exceed the purchases by €100k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The largest single trade was a sale of €94k by HRT Financial LP, published on 19 August 2026, equal to 8.1% of the market capitalisation. The buyers include 1 major shareholder.
The latest purchase dates back some time: it was published 70 days ago, on 14 August 2026. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
For context, the typical company on the same exchange (median of 5,462 companies) published 28 filings over the same period, against 25 filings here. Our records for Profusa, Inc. go back to 2026, with 8 purchases and 6 sales on the open market in total.
For comparison within the same sector, see the insider buying recorded at Xenon Pharmaceuticals Inc. and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
25
Thresholds
n/a
Buy Volume
€32,054
8 ops. · all time
Sell Volume
€132,443
6 ops. · all time
Who traded when
BuySaleHRT Financial LP8 buys6 sales
Since the insiders bought
- -42.8%Entry US$4.53 · Close at T+30 US$2.59
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.89
Analyst consensus
Income statement
RevenueUS$86.5k
EBITDA-US$33.3M-38499% margin
Net income-US$35.8M0.0% margin
Valuation
PER (trailing)0.0x
Beta0.50
Balance sheet & cash
Total debtUS$14.8M
Free Cash Flow-US$16.3M
Profitability & ownership
ROA-725.3%
% insiders41.7%
% institutions3.5%
Last declaration on 4 September 2026
Declarations25 total
301,991 shares0Common StockSEC:0001213900-26-097490:1
54,323 shares0Common StockSEC:0001213900-26-097491:0
301,991 shares0Common StockSEC:0001213900-26-097491:1
32,018 shares0Common StockSEC:0001213900-26-097490:0
18,395 shares@ US$5.948.13% mcap57.3% of flowCommon StockSEC:0001475597-26-000207:0
301,991 shares@ US$4.2896.51% mcap100.0% of flowCommon StockSEC:0001213900-26-091841:0
301,991 shares@ US$4.2896.51% mcap100.0% of flowCommon StockSEC:0001213900-26-091839:0
3,163 shares@ US$0.9020.21% mcap1.5% of flowCommon StockSEC:0001475597-26-000204:0
42,411 shares@ US$0.8882.81% mcap19.9% of flowCommon StockSEC:0001475597-26-000201:1
5,585 shares@ US$0.9640.40% mcap2.8% of flowCommon StockSEC:0001475597-26-000201:0
Canonical exit: 10 Nov 2026 (T+90)
4,016 shares@ US$0.9440.28% mcap2.0% of flowCommon StockSEC:0001475597-26-000194:0
Canonical exit: 8 Nov 2026 (T+90)
2,280 shares@ US$0.970.17% mcap1.2% of flowCommon StockSEC:0001475597-26-000194:1
383 shares@ US$0.9420.027% mcap0.2% of flowCommon StockSEC:0001475597-26-000191:0
926 shares@ US$0.9430.065% mcap0.5% of flowCommon StockSEC:0001475597-26-000191:1
Canonical exit: 4 Nov 2026 (T+90)
924 shares@ US$0.9460.065% mcap0.5% of flowCommon StockSEC:0001475597-26-000191:2
14,556 shares@ US$0.9581.04% mcap7.3% of flowCommon StockSEC:0001475597-26-000185:0
Canonical exit: 1 Nov 2026 (T+90)
1,368 shares@ US$0.9540.098% mcap0.7% of flowCommon StockSEC:0001475597-26-000185:1
Canonical exit: 2 Nov 2026 (T+90)
1,063 shares@ US$1.010.081% mcap0.6% of flowCommon StockSEC:0001475597-26-000183:0
Canonical exit: 28 Oct 2026 (T+90)
8,811 shares@ US$1.050.69% mcap4.9% of flowCommon StockSEC:0001475597-26-000183:1
Canonical exit: 29 Oct 2026 (T+90)
1,310 shares@ US$1.010.10% mcap0.7% of flowCommon StockSEC:0001475597-26-000178:0
Canonical exit: 27 Oct 2026 (T+90)
818,961 sharesCommon StockSEC:0001213900-26-010524:0
4,743,750 sharesCommon StockSEC:0001213900-26-010520:0
107,750 sharesCommon StockSEC:0001213900-26-010492:0
553,665 sharesCommon StockSEC:0001213900-26-010228:0
30,000 sharesCommon StockSEC:0001213900-26-010226:0
25 of 25 declarations
About Profusa, Inc.
Profusa, Inc. is a company focused on developing health monitoring devices based on biosensor technologies. It aims to enhance healthcare through innovative solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
